Synthetic Biologics, Inc. SYN
Day range unavailable
52-week range unavailable
- Market cap
- 16.16M
- Shares out
- 15.84M
- Forward P/E
- -0.65
- Beta
- 1.39
- Analysts
- Buy
- Price target
- 5.50 (+439.2%)
- Earnings date
- Nov 2, 2022
2Y -3.28 (-76.28%)
Key statistics
- Enterprise value
- -34.57M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.26
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -720.63K
- Total cash
- 52.27M
- Total debt
- 1.70M
- Return on equity
- -26.26%
- Short % of float
- 2.74%
- 50-day average
- 1.27
- 200-day average
- 2.08
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 5.50
- Target (high)
- 7.00
- Strong buy3
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 2, 2022
Expected Nov 2, 2022. Consensus EPS estimate -0.39.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | 0.00 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 16, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 3, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- syntheticbiologics.com
News
Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc. 
SonicStrategy Closes $2.25 Million SYN Token Financing 
SonicStrategy Acquires Additional SYN Tokens and Announces Grant of Stock Options 
SonicStrategy Acquires 500,000 SYN Tokens, Expanding Treasury Exposure to On-Chain Derivatives 
Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients 
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript) 
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody 
Synthetic Biologics, Inc. (SYN) CEO Steven Shallcross on Q2 2022 Results - Earnings Call Transcript 
Earnings Scheduled For August 11, 2022 
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
Your note
Sign in to keep a note on SYN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALLANTYNE CHARLES EVAN | Chief Financial Officer | Purchase | May 21, 2014 | 10,000 |
| KANZER STEVE H | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 29, 2014 | 0 |
| KIRK RANDAL JOE | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 2, 2019 | 0 |
| KRAWS JEFFREY J | Director | Conversion of Exercise of derivative security | Mar 13, 2017 | 228,773 |
| KUO JAMES S | Chief Executive Officer | Purchase | Aug 29, 2011 | 4,500 |
| LYON LYMAN MAX JR | Chief Executive Officer | Stock Award(Grant) | Dec 6, 2009 | 45,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group, Inc. (The) | 3.34% | 529,650 | 540.24K | Jun 29, 2022 |
| Blackrock Inc. | 1.19% | 188,569 | 192.34K | Jun 29, 2022 |
| Truist Financial Corp | 0.76% | 120,003 | 122.40K | Jun 29, 2022 |
| Geode Capital Management, LLC | 0.74% | 116,584 | 118.92K | Jun 29, 2022 |
| State Street Corporation | 0.31% | 48,692 | 49.66K | Jun 29, 2022 |
| Northern Trust Corporation | 0.21% | 33,079 | 33.74K | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.09% | 330,874 | 337.49K | Jun 29, 2022 |
| Vanguard Extended Market Index Fund | 1.23% | 194,212 | 198.10K | Jun 29, 2022 |
| Fidelity Extended Market Index Fund | 0.43% | 68,203 | 69.57K | Aug 30, 2022 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.09% | 13,567 | 13.84K | Jul 30, 2022 |
| Fidelity Series Total Market Index Fund | 0.09% | 14,856 | 15.15K | Aug 30, 2022 |
| Fidelity Total Market Index Fund | 0.06% | 9,757 | 9.95K | Aug 30, 2022 |